Search
Amineptine
go.drugbank.com/drugs/DB04836ApprovedIllicitWithdrawnThe Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until
Sequestosome-1
go.drugbank.com/bio_entities/BE0014160TargetHumansMolecular adapter required for selective macroautophagy (aggrephagy) by acting as a bridge between polyubiquitinated proteins and autophagosomes (PubMed:15340068, PubMed:15953362, PubMed:16286508, PubMed … following ubiquitination by RNF26, attracts specific vesicle-associated adapters, forming a molecular bridge that restrains cognate vesicles in the perinuclear region and organizes the endosomal pathway for
Synonyms: Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDaManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedIt is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder. … Manganese gluconate is a manganese salt of gluconic acid with the chemical formula C12H22MnO14 x 2H2O.
Mixtures: Multi-force for Women Tab, Cal-mag Plus K, Mn and Zn CapletsSalt-losing Androgenital syndrome
go.drugbank.com/conditions/DBCOND0123106Drugs: FludrocortisoneSynonyms: Salt-losing Androgenital syndromeAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[L2931] It is administered orally as the salt form avatrombopag maleate. … This approval was supported by results from the AVA-PED-301 phase 3 study, which demonstrated durable platelet responses and favorable safety in children with persistent or chronic immune thrombocytopenia
Levoketoconazole
go.drugbank.com/drugs/DB05667ApprovedIt possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate. … [A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563]
Categories: Corticosteroids for Systemic UseTazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity
Mixtures: Zerbaxa 1.5g powder for solution for injection, ZERBAXA POWDER FOR SOLUTION FOR INJECTION 1G/0.5GCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseBecaplermin
go.drugbank.com/drugs/DB00102ApprovedInvestigationalBecaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. … Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.
Categories: Preparations for Treatment of Wounds and UlcersCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigational[L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … [L10403] It was developed by Global Blood Therapeutics, Inc.